Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
NervGen Pharma Corp. (NGEN) had Return on Tangible Equity of -172.92% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-21.10M |
|
-- |
|
-- |
|
$8.81M |
|
$-8.81M |
|
$-12.29M |
|
$-21.10M |
|
$-21.10M |
|
$-21.10M |
|
$-21.10M |
|
$-21.10M |
|
$-21.10M |
|
$-8.81M |
|
$-8.80M |
|
92.44M |
|
92.79M |
|
$-0.23 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$64.87M |
|
-- |
|
$0.28M |
|
$65.14M |
|
$52.67M |
|
-- |
|
-- |
|
$52.67M |
|
$12.48M |
|
$12.20M |
|
$12.48M |
|
106.41M |
|
| Cash Flow Statement Financials | |
$-10.06M |
|
$0.01M |
|
$58.45M |
|
$15.94M |
|
$62.69M |
|
$46.75M |
|
$2.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-169.11% |
|
|
Return on Tangible Equity |
-172.92% |
-32.39% |
|
-169.11% |
|
$0.12 |
|
$-0.11 |
|
$-0.11 |
|